

Joint Working EXECUTIVE SUMMARY

Published on www.astrazeneca.co.uk

Joint Working between AstraZeneca UK Ltd and Wirral University Teaching Hospital NHS

Document Number 311-1-ES

Date of Preparation Oct 2025

Project title	Arrowe Park Severe Asthma Nurse
Aims and Objectives	• Optimise the identification and management of Severe Asthma patients • Increase identification of suspected Severe Asthma patients • Increase number of suspected Severe Asthma patient reviews • Increase uptake / initiation of biologics where appropriate to do so • Reduction in OCS usage in patients identified • Improvement in symptoms / ACQ score) in all patients identified • Accelerating SA patient pathway timelines – time to MDT / appropriate treatment.
Anticipated benefits	It is expected that this project will support the following groups in the following ways: Patient: • Optimised Treatment: Appropriately being identified as a patient who may benefit from alternative treatment options for severe asthma. • Appropriate initiation and optimisation of medicines by Specialists in-line with local and national guidelines Fewer Hospital Visits: Early, customised interventions will likely lead to a reduction in non-elective admissions and readmissions, easing the burden on patients. Improved Care Quality: Patients may experience significant improvements in the quality of care they receive, potentially enhancing their quality of life. NHS: • Decreased Waiting Times: The project aims to reduce waiting times for specialist consultations, improving patient flow. • Improved Care Quality: The overall quality of care for patients with severe asthma will be enhanced. • Reduced Unplanned Admissions: In the longer term, the project is expected to improve patient flow and reduce the total number of unplanned admissions and inpatient bed days. AstraZeneca: • Align with Medical Mission: The project supports AstraZeneca's strategy to improve the lives of asthma patients, including those with severe asthma, by promoting early identification and optimal treatment. • Optimised Medicine Use: The initiative supports the optimisation of medicines for the treatment of severe asthma. While the prescribing of AstraZeneca medicines may increase, the decision to prescribe will remain clinician-led in accordance with local protocols and guidelines. • Share Best Practices: A successful project with demonstrable outcomes will allow

	AstraZeneca to share best practices across the UK healthcare system. • Enhanced Reputation: The project is anticipated to improve AstraZeneca's corporate reputation and trust amongst the NHS and patients
Timeline	The project will commence on the 01 Nov 2025 and will continue for a duration of 12 months.
References	[References]